SCHEMBL4876097

SCHEMBL4876097

CC(C)(C)[Si](C)(C)OCCN(C#N)c1ccc(NC(=O)c2sccc2C(=O)Nc2ccc(Cl)cn2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 14/20 0.38
F2 P00734 12/20 0.38
KLKB1 P03952 1/20 0.38
ELANE P08246 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4881051 0.86 RAB9A (0.38) MEN1KMT2ASMN1; SMN2CYP1A2CYP2D6
SCHEMBL4885688 0.85 RAB9A (0.35) F10MEN1KMT2ASMN1; SMN2CYP1A2
SCHEMBL14066578 0.85 F10 (0.43) F10F2KLKB1ELANEMEN1
SCHEMBL4882648 0.85 F10 (0.43) F10F2KLKB1ELANEMEN1
SCHEMBL4880879 0.82 RAB9A (0.37) MEN1KMT2ASMN1; SMN2CYP1A2CYP2D6
SCHEMBL4879114 0.80 F2 (0.38) F10F2KLKB1ELANENPC1
SCHEMBL4878149 0.80 LMNA (0.41) SMN1; SMN2CYP1A2CYP2D6CYP2C19LMNA
SCHEMBL4876089 0.79 F10 (0.37) F10F2KLKB1ELANESMN1; SMN2
SCHEMBL3613978 0.78 GCGR (0.40) F10GAAMAPTHTTNR3C1
SCHEMBL3618881 0.78 LMNA (0.40) LMNAPOLBNR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214533-A1 Cyclic Iminocarbamates And Their Use F2, UQCRB, F12 F10 26/4885F2 1/4885KLKB1 2528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.